| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.0095 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.8 |